{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Grade 3 or higher increase in Potassium"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Grade 3 or higher increase in Calcium"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9"},{"groupId":"OG001","value":"7.1"}]}],"title":"Grade 3 or higher increase in Magnesium"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4"},{"groupId":"OG001","value":"0"}]}],"title":"Grade 3 or higher increase in Sodium"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.7"},{"groupId":"OG001","value":"14.3"}]}],"title":"Grade 3 or higher increase in Alanine aminotransferase"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.7"},{"groupId":"OG001","value":"14.3"}]}],"title":"Grade 3 or higher increase in Aspartate aminotransferase"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5"},{"groupId":"OG001","value":"0"}]}],"title":"Grade 3 or higher increase in Bilirubin"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9"},{"groupId":"OG001","value":"7.1"}]}],"title":"Grade 3 or higher increase in Creatinine"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.2"},{"groupId":"OG001","value":"21.4"}]}],"title":"Grade 3 or higher increase in Urate"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9"},{"groupId":"OG001","value":"14.3"}]}],"title":"Grade 3 or higher increase in Direct bilirubin"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9"},{"groupId":"OG001","value":"21.4"}]}],"title":"Grade 3 or higher increase in Glucose"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Grade 3 or higher increase in Alkaline phosphatase"}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"14"}],"units":"Participants"}],"groups":[{"description":"Participants with relapsed/refractory MCL received conditioning chemotherapy consisting of fludarabine 30 mg/m\\^2/day and cyclophosphamide 500 mg/m\\^2/day IV infusion for 3 days followed by a single infusion of brexucabtagene autoleucel at a targeted dose of 2 x 10\\^6 anti-CD19 CAR T cells/kg, with a maximum dose of 2 x 10\\^8 anti-CD19 CAR T cells for participants ≥ 100 kg on Day 0.","id":"OG000","title":"Cohort 1: 2 x 10^6 Brexucabtagene Autoleucel"},{"description":"Participants with relapsed/refractory MCL received conditioning chemotherapy consisting of fludarabine 30 mg/m\\^2/day and cyclophosphamide 500 mg/m\\^2/day IV infusion for 3 days followed by a single infusion of brexucabtagene autoleucel at a targeted dose of 0.5 x 10\\^6 anti-CD19 CAR T cells/kg, with a maximum dose of 0.5 x 10\\^8 anti-CD19 CAR T cells for participants ≥ 100 kg on Day 0.","id":"OG001","title":"Cohort 2: 0.5 x 10^6 Brexucabtagene Autoleucel"}],"paramType":"NUMBER","populationDescription":"Participants from the Safety Analysis Set were analyzed.","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Percentage of Participants With Increase in Post-brexucabtagene Autoleucel Infusion Chemistry Toxicity Values by Worst Toxicity Grade","type":"SECONDARY","unitOfMeasure":"percentage of participants"}